Overlevelsesraten efter 12 måneder var 89, 2% for Advagraf og 90, 8% for Prograf; i Advagrafgruppen døde 25 patienter (14 kvinder, 11 mænd), og i Prografgruppen døde 24 patienter (5 kvinder, 19 mænd).
The treatment difference (Advagraf – Prograf) was 3.3% (95% confidence interval [-5.7%, 12.3%]). The 12-month patient survival rates were 89.2% for Advagraf and 90.8% for Prograf; in the Advagraf arm 25 patients died (14 female, 11 male) and in the Prograf arm 24 patients died (5 female, 19 male).